More articles from Point and Counterpoint

  • Screening mammography starting at age 40: Still relevant
    Karthik Ghosh, MD, Dietlind Wahner-Roedler, MD and Kathleen Brandt, MD
    Cleveland Clinic Journal of Medicine May 2015, 82 (5) 276-279; DOI: https://doi.org/10.3949/ccjm.82a.14155

    In women in their 40s, the incidence of breast cancer is low but the risk of a tumor being aggressive is especially high.

  • Annual mammography starting at age 40: More talk, less action?
    Pelin Batur, MD, FACP, NCMP and Judith M. E. Walsh, MD, MPH
    Cleveland Clinic Journal of Medicine May 2015, 82 (5) 272-275; DOI: https://doi.org/10.3949/ccjm.82a.14156

    In view of the potential harm, we question annual screening starting at age 40.

  • The apples and oranges of cost-effectiveness: A rejoinder
    Vinay Prasad, MD
    Cleveland Clinic Journal of Medicine September 2012, 79 (9) 610-611; DOI: https://doi.org/10.3949/ccjm.79a.12129

    The author of the commentary replies.

  • The apples and oranges of cost-effectiveness: A rejoinder
    Chiedozie I. Udeh, MD, MHLTHEC and Belinda L. Udeh, PhD, MPH
    Cleveland Clinic Journal of Medicine September 2012, 79 (9) 608-610; DOI: https://doi.org/10.3949/ccjm.79a.12123

    A recent CCJM commentary used straw men to indict cost-effectiveness research.

  • Interpreting the Courage Trial
    Deepak L. Bhatt, MD
    Cleveland Clinic Journal of Medicine September 2007, 74 (9) 618-620;

    We are fortunate to have a point-counterpoint between Dr. William Boden, the principal investigator of the Clinical Outcomes Utilizing Percutaneous Coronary Revascularization and Aggressive Drug Evaluation (COURAGE) trial, and Dr. Dean Kereiakes, a leading interventional cardiologist.

  • Cox - 2 Inhibitors and Cardiovascular Risk
    Debabrata Mukherjee, MD, Steven E. Nissen, MD and Eric J. Topol, MD
    Cleveland Clinic Journal of Medicine November 2001, 68 (11) 963-964;

    Our study had limitations, but we believe our hypothesis is plausible, our methods were valid, and our conclusions are sound.

  • Cox - 2 Inhibitors and Cardiovascular Risk
    John Lipani, MD
    Cleveland Clinic Journal of Medicine November 2001, 68 (11) 961-962;

    Unless a clear cause-and-effect relationship can be proved between COX-2 inhibitors and cardiovascular events, we should go on using these drugs.